What can research reveal before cognitive changes become obvious? On World Alzheimer’s Day 2026, that question brings together some of the field’s biggest priorities: understanding risk, improving timely diagnosis, measuring cognitive change and building stronger evidence for what comes next.21 September – World Alzheimer’s Day. Image by CogniFit. September 21 marks World Alzheimer’s Day, part of the global awareness campaign coordinated by Alzheimer’s Disease International (ADI). This year’s theme – “The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters” – focuses attention on timely diagnosis and on what earlier knowledge can mean for people living with dementia, their families and caregivers.The scale of the challenge remains enormous. According to the World Health Organization’s latest guidance, published in July 2026, more than 57 million people worldwide live with dementia, and nearly 10 million people are newly diagnosed every year. Alzheimer’s disease is the most common form of dementia, accounting for an estimated 60–70% of cases. But World Alzheimer’s Day is not only about the scale of the problem. It is also about what science still needs to understand, and how better research can help move the field forward.CogniFit has also contributed to the broader Alzheimer’s conversation by highlighting emerging research and supporting relevant awareness initiatives. Recent examples include our coverage of a 2026 systematic review exploring GLP-1 receptor agonists and Alzheimer’s pathology and our participation in a 2023 awareness campaign led by Accexible focused on speech-based detection of cognitive decline.Dementia is influenced by many factors, and not all of them can be modified. However, WHO’s updated 2026 guidance reports that up to 45% of dementia risk can be attributed to potentially modifiable factors, including tobacco and alcohol use, physical inactivity, social isolation, air pollution, high blood pressure and diabetes. This does not mean that dementia can always be prevented in an individual. It does mean that risk reduction across the life course has become an important part of the global conversation alongside diagnosis, treatment, care and research.At the same time, Alzheimer’s research is expanding across biomarkers, neuroimaging, genetics, cognitive change, artificial intelligence and potential new treatments.Behind all of these areas lies the same basic requirement: reliable evidence.Clinical trials are taking center stage in 2026This year, Alzheimer’s Disease International is putting a particular spotlight on clinical research. The World Alzheimer Report 2026 focuses on dementia clinical trials and the role they play in advancing future approaches to diagnosis, treatment and care.As of January 1, 2026, 158 drugs were being evaluated across 192 active Alzheimer’s clinical trials, requiring nearly 55,000 participants.For pharmaceutical companies, MedTech organizations, CROs and academic research teams, this growing pipeline creates an important practical challenge: how to follow participants over time and measure meaningful change consistently across studies.When cognition is one of those outcomes, how it is measured matters.Digital cognitive tools are already part of the research landscapeDigital technologies are increasingly being studied in cognitive aging and dementia-related research.A 2025 scoping review in the Journal of Medical Internet Research examined 39 studies of digital tools used in an Alzheimer’s or dementia context. The review included CogniFit General Training among the computerized cognitive-training tools identified in the literature. It also found that almost 80% of the tools reviewed were still at relatively early stages of maturity or evaluation, highlighting the need for larger and longer-term studies.In this context, digital cognitive tools can support research by helping teams measure and track cognitive outcomes over time within structured study protocols. CogniFit technology in independent cognitive researchCogniFit technology has also been used in independent research involving populations relevant to dementia-risk research.One example is a U.S. Department of Veterans Affairs–sponsored randomized clinical trial involving older veterans with type 2 diabetes who did not have dementia. A study published in the Journal of Alzheimer’s Disease described recruitment for the trial, which used Personal Coach from CogniFit as the computerized cognitive-training program.This illustrates how digital cognitive technology can be incorporated into independent scientific research when cognition is one of the outcomes being studied.Alzheimer’s research is becoming increasingly multidisciplinaryCognitive measurement is only one part of a much broader research landscape.A 2025 review in Acta Pharmaceutica Sinica B examined how artificial intelligence, computational biology and systems biology are being applied to Alzheimer’s research across areas including biomarkers, neuroimaging, disease mechanisms and drug development.Together, these developments point to an increasingly multidisciplinary approach in which cognitive outcomes, biomarkers, imaging and computational methods can contribute different pieces of evidence.The challenge is not simply to collect more data, but to collect the right data consistently, and understand what each measure adds.From cognitive research to clinical trialsCogniFit provides digital tools for researchers studying cognition across different populations and study designs.CogniFit offers dedicated solutions for both academic research and clinical trials involving cognitive measurement. The CogniFit Cognitive Research Platform helps researchers configure studies, manage participants and collect cognitive data, while the CogniFit Clinical Trials solution supports research teams conducting commercial and clinical studies.CogniFit technologies have also been used and evaluated in peer-reviewed research across different populations and research settings. Explore the science behind CogniFit.For pharmaceutical, MedTech, CRO and academic teams working on studies in which cognition is relevant, digital cognitive measurement can therefore be one part of a broader research toolkit alongside biomarkers, imaging, clinical measures and other study endpoints.World Alzheimer’s Day is also a call for better researchWorld Alzheimer’s Day brings attention to people living with dementia, their families and caregivers. It also highlights the importance of awareness, timely diagnosis, risk reduction, appropriate care and continued scientific research.But every potential advance begins much earlier, with a question that needs to be tested.Better research depends on rigorous study design, meaningful endpoints and reliable data. As Alzheimer’s research continues to evolve, combining cognitive, biological and digital measures may help researchers build a clearer picture of change over time and generate stronger evidence for future advances.CogniFit technologies are discussed here in the context of scientific research and cognitive measurement. This article does not state or imply that CogniFit products diagnose, treat, cure, mitigate or prevent Alzheimer’s disease or other forms of dementia. ReferencesAlzheimer’s Disease International. World Alzheimer’s Month 2026 Campaign Toolkit. 2026.https://www.alzint.org/get-involved/world-alzheimers-month/resources/world-alzheimers-month-2026-campaign-toolkit/World Health Organization. New WHO guidelines: up to 45% of dementia risk could be prevented or delayed. July 15, 2026.https://www.who.int/news/item/15-07-2026-new-who-guidelines–up-to-45–of-dementia-risk-could-be-prevented-or-delayedCummings JL, Zhou Y, Yang Y, et al. Alzheimer’s disease drug development pipeline: 2026. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2026.DOI: https://doi.org/10.1002/trc2.70251de Rijke TJ, Engelsma T, Ng CH, et al. Digital Tools for People Without an Alzheimer Disease or Dementia Diagnosis: Scoping Review. Journal of Medical Internet Research. 2025;27:e64862.DOI: https://doi.org/10.2196/64862Karran M, Guerrero-Berroa E, Schmeidler J, et al. Recruitment of Older Veterans with Diabetes Risk for Alzheimer’s Disease for a Randomized Clinical Trial of Computerized Cognitive Training. Journal of Alzheimer’s Disease. 2019;69(2):401–411.DOI: https://doi.org/10.3233/JAD-180952Jiang S, Tian Z, Yang Y, et al. New insights into translational research in Alzheimer’s disease guided by artificial intelligence, computational and systems biology. Acta Pharmaceutica Sinica B. 2025;15(10):5099–5126.DOI: https://doi.org/10.1016/j.apsb.2025.08.015The post World Alzheimer’s Day 2026: Why Better Cognitive Research Matters More Than Ever appeared first on CogniFit Blog: Brain Health News.